Clinical Trials

Title   A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemothera
Description   This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
IRB Number   18-002
Treatment   Oncology - Breast Cancer
Status   Active
Principal Name   Carole Norden, M.D.
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us